Aspergillomas from Gastrointestinal Tract: a case report and review of the literature Authors: Hui Meng, Fang He, Xiao hong Lin, Xianrang Yan, Xiaolong She, Lijuan Lu, Xuetao Yu Published: 2024 ABSTRACT AbstractGastrointestinal (GI) aspergillosis is a rare and fatal complication in immunocompromised patients. We present the case of a 72-year-old patient with unexplained recurrent pancytopenia who presented with fever, constipation, abdominal distention, and jaundice. Imaging revealed a mass in the ileocecal junction, and biopsy revealed Aspergillus hyphae infiltrating the bowel wall. He had no evidence of pulmonary, sinus, or central nervous system Aspergillus infection. After 1 month of antifungal treatment with oral isavuconazole, he recovered well and was discharged. The clinical manifestations of GI aspergillosis are non-specific. This case highlights the importance of increasing the awareness regarding GI aspergillosis in high-risk patients without pulmonary involvement.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-024-10278-3.Keywords: Case report, Gastrointestinal aspergillosis, Pancytopenia, Mass, Isavuconazole Introduction Invasive aspergillosis (IA) is a life-threatening opportunistic infection in immunocompromised patients, particularly those with prolonged neutropenia and received high-dose corticosteroids or immunosuppressive therapy [1, 2]. Aspergillus species are often inhaled or ingested as airborne spores; therefore, IA typically involves the respiratory tract (including the lungs and sinuses). However, these species may infect other organs by hematogenous spread. Gastrointestinal (GI, stomach to rectum) aspergillosis is a seldom but fatal extrapulmonary IA (mortality rate of 37%) [3] that is usually observed as a part of disseminated infection. Primary GI aspergillosis is rare, even in immunocompromised hosts [4]. Owing to the poor specificity of symptoms and imaging, the diagnosis of GI aspergillosis infrequently occurs before autopsy [5]. Hemorrhage, ulcer, perforation, and necrotic lesions are common pathological lesions, while pseudotumour is rare [6–9]. Herein, we report describes the presentation, diagnosis and management of a patient with primary GI aspergillomas, which is pathologically characterized by rare pseudotumour. We performed a systematic review of the literature as well. Especially high-risk patients, we suggested early screening for endoscopy and early aggressive antifungal therapy to avoid potential surgery. Materials and methods A systematic literature review was performed from inception to July 2024, using PubMed database. The following search terms: “aspergillosis”, “invasive aspergillosis”, “disseminated aspergillosis” and “gastrointestinal”, “intestinal”. 42 articles were identified, patient characteristics are summarized in Table 1. Table 1Literature reviewAuthor, yearPatient No.Age, yearsGenderUnderlying diseaseGI presentationImaging featuresPathological manifestationPortion of GI tract involvedGM serum testDiagnosisprocedureSurgical interventionAntifungal treatmentDuration of treatmentSecondary disseminationOutcomeWeingrad DN et al. 1982138MaleALLAbdominal pain, diarrhea, and GI bleedingFluid-filled cecumPerforation with surrounding abscessesCaecumNegativeLaparotomyYesAmB6 monthsLungSurvivalKinder RB et al. 1985137FemalPost-renal transplantation, GVHDGI bleedingNAHaemorrhagic ulcerColonNALaparotomyYesAmBNRCNS, spleen and liverDeathCappell MS et al. 1991150MaleAIDSDiarrhea, vomitDiffuse irregularities of the esophageal mucosaUlcersEsophagus, stomach, small intestine and colonNAAutopsyNoNoNANoDeathCohen R et al. 1992133MaleAMLDiarrhea and abdominal painNANecrosisIleumNALaparotomyYesAmBNRLung and liverDeathPrescott RJ et al. 19921415-73 (median: 61)Femal (n=8) Male (n=6)Lymphoma (n=8), myelodysplasia (n=2), breast carcinoma (n=2),diabetes mellitus (n=2), CML (n=1), seminoma (n=1), gastric cancer (n=1)Diarrhea and vomit (n=7), GI bleeding (n=5), abdominal pain (n=6), oral thrush (n=4), abdominal distension (n=3), none (n=1)NRUlcers (n=8), pseudomembranous (n=3), segmental lesions (n=3), polypoid masses (n=2), mucosal flecks (n=2)Small intestine (n=13), large bowel (n=6), esophagus (n = 5), stomach (n=3)NRAutopsyNRYes (n=6), No (n=8)NRNo (n = 2)Lung (n = 9)Liver (n = 2)Spleen (n = 2) CNS (n = 1)DeathFoy TM et al. 199410.4FemalSCIDDiarrheaNAUlcersColonNALaparotomyYesNoNALungDeathPrescott RJ et al. 1994162MaleCMLMalabsorption and diarrheaNo abnormalityUlcers and aspergillomaEsophagus and stomachNAAutopsyNoAmBNRLungDeathJH Choi et al. 1997135MaleAMLNausea, vomit, and odynophagiaNAUlcersEsophagusNAEndoscopyNoAmBNRNoSurvivalYong S et al. 2000136MaleCMLDiarrhea and abdominal painNAPseudomembranousStomachNAAutopsyNoAmB24 daysLungDeathIbrahim AH et al. 2000121MaleNoDiarrhea with malabsorption and abdominal distentionMass attached to the intestine and abdominal wallMassIleocecal junction, colon,NALaparotomyYesAmB39 daysBladderDeathShah SS et al. 2001168MaleAMLAbdominal pain and constipationSmall bowel obstruction with intestinal wall thickeningUlcersJejunum and ileumNALaparotomyYesNoNANoDeathFranciosi CM et al. 200212.5MaleDiGeorge’s syndromeGI bleeding and abdominal painPneumoperitoneumPerforated ulcersStomachNALaparotomyYesYesNRCNSSurvivalSanders DL et al. 2003141FemalARDS, ARF, sepsis, longterm mechanicalventilationGI bleedingNAUlcers and pseudomembranousStomachNALaparotomyYesYesNRNoDeathTrésallet C et al. 2004157FemalLymphomaAbdominal pain, diarrhea, abdominal distentionand constipationSmall-bowel distention with a thickened wall of ileumNecrosis and ulcersSmall intestinePositivelaparotomyYesVoriconazoleNRLungSurvivalChionh F et al. 2005171MaleAMLEpigastric pain and GI bleedingNAExophytic lesionEsophagusNAEndoscopyNoVoriconazole to itraconazole12 weeksNoSurvivalChaudhary A et al. 2006145FemalCarcinomaof breastConstipation, abdominal pain and distentionDistended bowel loops and airfluid levelsNecrosisSmall intestinePositiveLaparotomyYesAmB2 weeksLungSurvivalP. Eggimann et al. 2006252-65 (median: 59)Male(n=2)AML (n=2)Abdominal pain (n=2)NRNecrotic mass (n=2)Jejunum (n=1), ileum (n=1)NALaparotomy (n=2)Yes (n=2)AmB (n=2)16 days and 28 daysLung (n=1), No (n=1)Death (n=1), Survival (n=1)R. S. Jayshree et al. 2006118MaleAMLDiarrheaNANRNRNAFecal cultureNoAmB14 daysLungSurvivalKayiran P et al. 20072six-month and four-monthMale(n=2)Primary immunodeficiency syndromes and transient hypogammaglobulinemiaDiarrhea (n=2), vomit (n=1)NAPseudomembranes (n=1), ulcers (n=1)Duodenum (n=1), stomach (n=1)NAEndoscopy (n=2)NoAmB (n=2)3 weeksNoSurvivalU. Mohite et al. 2007146MaleGranulocytic sarcomaDiarrhea, abdominal pain and abdominal distentionDiffusely thickened bowel wallIschaemic haemorrhagic necrosisColonNALaparotomyYesCaspofungi2 weeksNoSurvivalGonzález-Vicent M et al. 2007119MaleWilms’ tumorAbdominal pain and GI bleedingBowel obstructionPerforated ulcerIleumNALaparotomyYesAmB11NoDeathTrésallet C et al. 2010134FemalSystemic sclerosis overlapsyndromeAbdominal painGastric wall thickening and pneumoperitoneumPerforated ulcerStomachNALaparotomyYesYesNRNoDeathE. Kazan et al. 20102118-70 (median: 54)Femal (n=12) Male (n=9)AML (n = 10),Accelerated CML (n = 2),ALL (n = 2),MM (n = 3),Lymphoma (n = 2),MDS (n = 1)Diarrhea (n=10), abdominal pain (n=17), GI bleeding (n=7), Intestinal occlusion (n=6), perforation (n=1)Normal(n=2/14), intestinal thickening of intestinal wall(n=10/14), masses(n=2/14)Ulcers (n=3), Perforation (n=3), necrosis (n=3), pseudotumour (n=1)Small intestine (n=8), duodenum (n=4), colon (n=4), stomach (n=3), appendix (n=1), rectum (n=1)NA (n=1), Negative (n=4), Positive (n=16, median 3.3)Endoscopy (n=6), Laparotomy (n=10), Autopsy (n=5)Yes (n = 12)No (n = 9)Voriconazole (n = 8), liposomal AmB (n = 4)NRNo (n = 8)Lung (n = 12)CNS (n = 4)Pancreas liver (n = 2)Adrenal gland (n = 1)Skin (n = 1)Heart (n = 2)Spleen (n = 1)Kidney (n = 1)Survival (n = 8)Death (n = 13)Marchesi F et al. 2011166FemalALLMelena, vomit and abdominal painThickening of jejunum walls with submucosal edemaUlces and necrosisStomach and duodenumPositiveAutopsyNoVoriconazoleNRNoDeathMora D et al. 2013165FemalAML, recto-sigmoidal adenocarcinomaAbdominal pain, constipation,and feverBowel mural thickening and dilatationUlcersColonPositiveEndoscopyNoVoriconazole72 hNoDeathKaraman I et al. 2013113FemalArthrogryposis multiplex congenita, mild mental retardation and pectus excavatumAbdominal pain, abdominal distention and vomitDilatation of stomachUlcers and necrosisGastric fundusNALaparotomyYesNANRNoSurvivalFieber JH et al. 2013147MaleHepatitis C, hemophilia A, ulcerative colitisAbdominal pain and GI bleedingPneumoperitoneum and ascitesIschaemic haemorrhagic necrosis, ulcerJejunum to ileumNAAutopsyYesNANALungDeathLi E et al. 2014163MaleAMLAbdominal distension, vomit and constipationSmall bowel mass and dilatationMassSigmoid colonNALaparotomyYesVoriconazole6 monthsCNSSurvivalBizet et al. 2014136FemalSeptic shock secondary to fourniergangreneGI bleedingNAUlcersColonNAEndoscopyNoVoriconazole30 daysNoSurvivalCha SA et al. 2015147MaleDiabetes mellitusAbdominal painMultifocal wall disruption of colon and peritoneal thickeningPerforationTransverse colonNALaparotomyYesLiposomal AmB and voriconazole49 daysNoSurvivalSulik-Tyszka B et al. 2016132FemalBudd-Chiari syndrome, failure of liverGI bleedingNAMicroabscessesStomachNAEndoscopyNoVoriconazoleNRLungSurvivalDecembrino N et al. 201616MaleAMLAbdominal painAperistaltic, fluid-filled, distended appendixGangrenous inflammationAppendixPositiveLaparotomyYesVoriconazole2 weeksNoSurvivalAvcu G et al. 201615MaleALLHaemorrhage, jaundice, abdominal distensionColonic mural thickening and pneumoperitoneumPerforationColonPositiveLaparotomyYesCaspofungi, voriconazole, posaconazole and AmB73 daysLung, nasal sinuses, kidney and spleenSurvivalAbdullGaffar B et al. 2017120MaleAlcoholic and smoker, malnutritionAbdominal pain, GI bleedingNAUlcers and granulomasEsophagusNAEndoscopyNoNR8 weeksNoSurvivalG. Di Franco et al. 2018143MaleAMLGI bleedingDistended bowel loopsPerforations and abscessesJejunum and mesentericPositiveLaparotomyYesVoriconazole and caspofungin2 months and 28 daysLungSurvivalCeylan B et al. 2019165MaleDiffuse large B-cell lymphomaAbdominal pain and vomitIncreased thickness of the jejunal wall, dilatation of the small intestines and pneumoperitoneumPerforated ulcer and necrosisSmall intestineNALaparotomyYesCaspofungin13 daysLungDeathDíaz Alcázar MDM et al. 2020172FemalCeliac diseaseAbdominal pain and constipationThickening and stenosis in the jejunum and ileumUlcers and stenosisJejunumNAEnteroscopyYesVoriconazoleNRCNS and lungDeathGuglielmetti S et al. 2020188FemalHyperparathyroidism, dyslipidemia,and nonrelevant cardiopathyVomit and diarrheaDiffuse intestinal dilatationUlcersStomach and colonNALaparotomyYesAmB1 weekLungDeathPuing AG et al.2022160FemalMMHeart-burn and swallowing foreign body sensationNAUlcersEsophagusPositiveEndoscopyNoVoriconazole12 weeksLungSurvivalQuintero O et al. 20222218-84 (median: 52.5)Femal (n=9) Male (n=13)Hematologic malignancy (n=14), solid organ transplant (n=3), autoimmune hepatitis (n=2), AIDS (n=1), COPD (n=1), IABP and ECMO (n=1)Abdominal pain (n=10), diarrhea (n=8), GI bleeding (n=6), nausea and vomit (n=6), low appetite (n=4), abdominal distension (n=9)Wall thickening small and large bowel (n=6/15), pneumatosis (n=4/15), increased fat stranding of the colon and ascites (n=3/15), dilatation of bowel (n=3/15), infarction or intramural hemorrhage (n=2/15), ileus or bowel obstruction (n=2/15)Mucosal flecks (n=5), Ulcers (n=6), Colitis (n=1)Stomach (n=12), large bowel (n=6), small bowel (n=4), esophagus (n=2)NA (n=21), Positive (n=1)Laparotomy (n=5), Autopsy (n=17)Yes (n = 5)No (n = 17)Voriconazole (n=6), Isavuconazole (n=2), Posaconazole (n=1), Anidulafungin (n=3), Caspofungin (n=8), AmB (n=7),NRNo (n = 6),Lung (n = 16), Kidney (n = 6),CNS (n = 5), Heart (n = 4),Liver (n = 3),Artery/vein (n=3), Spleen (n = 2), Thyroid (n = 1),Abdominal/pelvic serosa (n=1), Mediastinum (n=1)Survival (n = 2)Death (n = 20)Hinojosa V et al. 2023151FemalCOVID-19GI bleedingNAUlcersStomachNAEndoscopyNoVoriconazole1 daysNoDeathAbi Rached V et al. 2024181MaleLung cancer, Gastric adenocarcinoma, Bladder cancer d, Colon cancerDysphagiaNAUlcersEsophagusNAEndoscopyNoVoriconazole4 weeksPericardiumDeathAbbreviations: GI, gastrointestinal; GM, galactomannan; ALL, acute lymphoblastic leukaemia; AmB, amphotericin B; GVHD, graft-versus-host disease; CNS, central nervous system; AIDS, acquired immune deficiency syndrome; AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; SCID, sever combined immunodeficiency disease; MM, multiple myeloma; MDS, myelodysplastic syndrome; COPD, chronic obstructive pulmonary disease; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygenation; NA, not available; NR, not report Literature review Small intestine (n=13), large bowel (n=6), esophagus (n = 5), stomach (n=3) No (n = 2) Lung (n = 9) Liver (n = 2) Spleen (n = 2) CNS (n = 1) Mass attached to the intestine and abdominal wall ARDS, ARF, sepsis, longterm mechanical ventilation Abdominal pain, diarrhea, abdominal distention and constipation Small intestine Carcinoma of breast Distended bowel loops and air fluid levels Systemic sclerosis overlap syndrome Gastric wall thickening and pneumoperitoneum AML (n = 10), Accelerated CML (n = 2), ALL (n = 2), MM (n = 3), Lymphoma (n = 2), MDS (n = 1) Yes (n = 12) No (n = 9) No (n = 8) Lung (n = 12) CNS (n = 4) Pancreas liver (n = 2) Adrenal gland (n = 1) Skin (n = 1) Heart (n = 2) Spleen (n = 1) Kidney (n = 1) Survival (n = 8) Death (n = 13) Abdominal pain, constipation, and fever Septic shock secondary to fournier gangrene Diffuse large B-cell lymphoma Increased thickness of the jejunal wall, dilatation of the small intestines and pneumoperitoneum Thickening and stenosis in the jejunum and ileum Hyperparathyroidism, dyslipidemia, and nonrelevant cardiopathy Diffuse intestinal dilatation Yes (n = 5) No (n = 17) No (n = 6), Lung (n = 16), Kidney (n = 6), CNS (n = 5), Heart (n = 4), Liver (n = 3), Artery/vein (n=3), Spleen (n = 2), Thyroid (n = 1), Abdominal/pelvic serosa (n=1), Mediastinum (n=1) Survival (n = 2) Death (n = 20) Abbreviations: GI, gastrointestinal; GM, galactomannan; ALL, acute lymphoblastic leukaemia; AmB, amphotericin B; GVHD, graft-versus-host disease; CNS, central nervous system; AIDS, acquired immune deficiency syndrome; AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; SCID, sever combined immunodeficiency disease; MM, multiple myeloma; MDS, myelodysplastic syndrome; COPD, chronic obstructive pulmonary disease; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygenation; NA, not available; NR, not report Presentation of the case A 72-year-old male with unexplained pancytopenia was admitted to the Department of Hematology in May 2022. He had a history of diabetes and chronic kidney disease. Pancytopenia was first noted 11 months prior when he was admitted to another hospital due to fever. The laboratory data revealed a white cell count (WCC) of 0.23/mm3, hemoglobin (Hgb) of 8.3 g/dL, and platelet count (Plt) of 81,000/mm3. During hospitalization, twice bone marrow biopsies were performed, both of which showed hypoplasia, which was suspected to be aplastic anemia. After antibiotic therapy, the patient’s condition improved, and he was discharged. The patient was readmitted in a similar condition after 3 months. On admission, his general condition was poor, and he complaining of pyrexia (temperature, 39.0 °C), shivers, fatigue, tachycardia, shortness of breath, and abdominal distension. The laboratory tests revealed a WCC of 0.46/mm3, an absolute neutrophil count of 0.01/mm3, an Hgb level of 9.3 g/dL, a Plt of 125,000/mm3, a hypersensitive C-reactive protein (hCRP) level of 189 mg/L (range, 0–10.0 mg/L), and a procalcitonin (PCT) level of 4.06 ng/mL (range, 0–0.05 ng/mL). Initially, broad-spectrum antibiotics (meropenem, moxifloxacin, and linezolid) were administered. Despite 2 weeks of antimicrobial therapy, the patient had persistent fever and respiratory distress. Subsequently, he was referred to the intensive care unit (ICU) because of clinical deterioration caused by severe sepsis. Thoracic computed tomography (CT) revealed aggravation of pneumonia, and mechanical ventilation was initiated upon ICU admission. Micafungin was added because of an increase in the level of (1,3) ß-D-glucan (657.2 pg/ml, range: 0–60 pg/ml) following its assay. Unfortunately, he developed carbapenem-resistant Pseudomonas aeruginosa (CRAP)-induced parotid abscess, bloodstream infection, and cholecystitis, as confirmed by serial cultures. Although systemic symptoms improved after 1 week of levofloxacin therapy, his GI symptoms (distension, constipation, and jaundice) remained overt. Point-of-care ultrasonography suggested cholecystitis with common bile duct dilatation. Advanced investigations, including abdominal contrast-enhanced CT (CECT), were performed to evaluate the etiology of the biliary dilatation; however, a contrast-enhanced mass was unexpectedly found in the ileocecal junction on day 23 (Fig. 1). Subsequently, colonoscopy and biopsy were performed to determine the etiology of the mass (Fig. 2). On day 30, microscopy of the biopsy specimen and the PSA strain revealed chronic inflammation with lymphocyte infiltration and invasion of numerous septate hyphae into the mucosa, compatible with Aspergillus (Fig. 3). Repeat chest CT scan revealed the absence of features of invasive aspergillosis. Moreover, the next-generation sequencing of bronchoalveolar lavage fluid investigations demonstrated no evidence of Aspergillus infection in the lung. The serum galactomannan (GM) antigen level was 9.82 µg/L(range 0–0.25 µg/L). Based on the clinical images and histopathological findings, the patient was diagnosed with primary GI aspergillosis. Abdominal contrast-enhanced computed tomography (CECT) showing a mass with contrast at the ileocecal junction (red arrowhead) Colonoscopy revealing a gross ulcer with necrotic tissue covering it at the ileocecal junction Photomicrograph of the biopsy specimen from the colon highlighting numerous Aspergillus species and lymphocytes infiltration (periodic acid silver staining, 200×). The inset shows Aspergillus hyphae branching at acute angle (periodic acid silver staining, 400×) As there were no serious abdominal complications, the patient was managed conservatively. After the diagnosis, voriconazole was added to initiate treatment. As the patient presented with intermittent fever, persistent GI symptoms (abdominal distension, constipation, and jaundice), and concurrent hepatic impairment, the antifungal agent was modified to oral isavuconazole (200 mg/day, q8h) on day 33. The patient’s WCC and Plt increased gradually to the normal range, accompanied by GI symptom improvement after 1 week of isavuconazole treatment. After 3 weeks of oral isavuconazole therapy, repeated abdominal CECT and colonoscopy revealed a significant reduction in the lesion (Sup Figs. 1–2). Moreover, histopathological analysis of the specimen revealed the absence of Aspergillus hyphae (Sup Fig. 3). The patient was discharged after 1 month of antifungal treatment; he had no relapse and lived independently after 12 months of follow-up. Review of the literature The review of the literature reveals 42 reports contained 98 patients of GI aspergillosis, most of them are case reports or case series. Data are summarized in Table 1. The mean age of patients was 46 years (range 0.3–88). There were 54 males (mean age: 43 years) and 44 females (mean age: 49 years), respectively. 94 patients had immunodeficiency disorder, the common underlying diseases included: varies hematologic malignancy (n = 62, 65.9%), solid tumor (n = 7, 7.4%), organ transplantation (n = 4, 4.3%). They were receiving immunosuppressive agents for either prophylaxis for or treatment. Other predisposing disease that may the development of IA included: primary immunodeficiency syndromes, AIDS (acquired immune deficiency syndrome), diabetes, septic shock, COVID-19, liver failure, alcoholic and malnutrition, ulcerative colitis, systemic sclerosis, COPD, IABP and ECMO. There were 67 reported deaths (mortality, 68.4%), including 41 patients diagnosed by autopsy (28.6%). Another 57 patients were diagnosed before death, of which 38 patients were diagnosed by postoperative pathology (38.8%), followed by endoscopy (n = 18, 18.4%) and another by repeated fecal culture (n = 1). GM antigen testing was performed in 30 patients, include positive results in 25 (83.3%). The differences in outcomes between surgical and antifungal treatment are shown in Fig. 4. The outcome on surgical and antifungal treatment Among these, 40 patients had lesion in small intestine (41.2%), 31 in the large intestine (31.9%), 30 in the stomach (31%), and 14 in the esophagus (14.4%). These lesions may be limited in the segmental intestinal or disseminated in multiple tracts. Isolated GI aspergillosis occurred in 34 of 98 patients (34.7%), while in disseminated cases, 54 patients were complicated by lungs (55.1%), followed by the central nervous system (n = 13, 13.3%). Atypical GI mucositis was the main clinical manifestation, included abdominal pain in 54 patients, diarrhea in 47, GI hemorrhage in 32, vomit in 21, abdominal distension in 19, constipation or occlusion in 12. The imaging of abdomen was performed in 52 patients, among which the thickening of GI wall was the most common abnormalities (n = 26), followed by GI dilatation (n = 12) and perforation (n = 9). Morphologically, there showed mixed lesions, including ulcers (n = 41), necrosis (n = 14), perforations (n = 11), mass (n = 8), mucosal flecks (n = 7) and pseudomembranous (n = 6), which may be single or multiple. Discussion IA mainly involves the lower respiratory tract and sinuses. Other sites of infection include the central nervous system, eyes, skin, kidneys, heart, liver, and GI tract [10, 11]. Most GI aspergillosis cases have been reported to be disseminated cases. Eggiman et al. [12] reviewed retrospective studies showing an incidence of 2%, of which only 0.7% were diagnosed with a primary GI tract infection. However, the true incidence may be underestimated. Another retrospective study from an autopsy case series reported that the incidence had increased to 17% (2–53%) [12]. Notably, it is difficult for Aspergillus spores to survive or obtain a favorable environment for colonization in the GI mucosa under physiological conditions. Unfortunately, when injury to the mucosal barrier or ostomy occurs in immunocompromised patients, the GI tract may be a portal of entry for Aspergillus [6, 13, 14]. We think that mucosal problems due to repeated infection and long-term antibiotic exposure may be potential risk of GI aspergillosis in our case. Due to differences in studied populations, the most common site of GI Aspergillus infection remains controversial [3, 4]. Nevertheless, the small intestine was the most involved organ in lower GI tract infections [3, 12, 15]. This is consistent with our retrospective findings. Many cases of GI aspergillosis are usually ignored because their clinical presentations are similar to those of non-specific enterocolitis, such as abdominal pain, diarrhea, GI hemorrhage, and abdominal distention [3, 15]. Notably, Aspergillus spp. can invade submucosal vessels [16], consequently becoming complicated by hemorrhage, perforation, abscess, and ileus [6, 15, 17]. In clinical practice, these symptoms are not singular manifestations as they are commonly overshadowed or mixed with varying systemic symptoms, which increases the difficulty of identification. Despite poor specificity, abdominal CT should be suggested in high-risk patients. Especially, radiological findings reveal distention with a segmental thickened of GI wall with inflammation around. These images features may be a non-specific warning sign of GI aspergillosis, highlighting the necessity for further screening in immunocompromised patients, particularly in those with compatible clinical manifestations and positive serum GM antigen test findings. Overall mortality rate of IA was 68.4% in our retrospective review, which was similar to the retrospective results of P. Eggimann et al. [12] This result may have been an overestimate because diagnosed by autopsy were also included, whose cause of death could have been multifactorial. The review result show surgical patients had a higher mortality rate, which may be associated with more severe complications in GI aspergillosis, such as perforation, severe bleeding, and intestinal obstruction. Given the high mortality rate associated with GI aspergillosis, aggressive endoscopic biopsy, and prophylaxis therapy should be considered for these patients to reduce delayed diagnosis and treatment. There is no consensus regarding the management, the selection of antifungal agents must be based on the clinical condition of the patient and the local epidemiology [18]. The IDSA guidelines [19] recommend voriconazole as the first-line treatment for IA; however, recently, it has been demonstrated that isavuconazole is as effective as voriconazole and is better tolerated [20]. Surgical intervention plays a key role in controlling complications [15]. In addition, another benefit of surgical procedures is the ability to provide diagnostic aid for cases with obscure diagnoses. In this case, the patient’s main symptoms included moderate abdominal distension and constipation. His pathological changes were necrotic pseudotumour, which was a rare granulomatous enteritis and was easily misdiagnosed as a tumoral lesion. Although GI aspergillosis-related aspergillomas is rare but possible, and may be complicated by mechanical bowel obstruction and granulomatous gastroenteritis [7, 8, 21]. The patient expressed gratitude for the timely diagnosis, which enabled avoidance of potential surgical risks. In addition, pancytopenia may be a potential clinical manifestation rather than a cause because the patient’s pancytopenia gradually recovered after treatment with isavuconazole, and did not relapse during follow-up. However, the real causal relationship between the two is unclear. Given the recurrence of pancytopenia before antifungal therapy and a prolonged debilitating condition, we speculated that the patient may have had a chronic low-burden infection of GI aspergillosis. Similar to the Splendore-Hoeppli phenomenon in which fungal components are coated with immune complexes that inhibit the effects of the fungus [22]. Conclusion The diagnosis of GI aspergillosis is difficult owing to the poor specificity of symptoms and imaging, especially for aspergillomas. An optimal therapy has not yet been established, and isavuconazole can be considered the preferred drug. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements The authors would like to thank Faqing Tian of the hematology department of The Second Affiliated Hospital, the Chinese University of Hong Kong, Shenzhen for helpful consultation opinion related to this work and Minghui Wang of the pathology department of The Second Affiliated Hospital, the Chinese University of Hong Kong, Shenzhen for providing us the histologic section. Author contributions Hui Meng and Fang He wrote the main manuscript text, Xiaohong Lin and Xiaolong She prepared figures, Lijuan Lu performed the data Curation, Xuetao Yu performed the supervision. Funding Medical and Health Science and Technology Project of Longgang District, Shenzhen, LGWJ2022-28. Data availability The datasets generated or analyzed during this study are available from the corresponding author on reasonable request, subject to patient privacy considerations. Declarations Ethics approval and consent to participate The patient provided written, informed consent for the publication of this case report and any accompanying images. Consent for publication Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement The datasets generated or analyzed during this study are available from the corresponding author on reasonable request, subject to patient privacy considerations.